These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 24638245)

  • 1. [No addition benefit from coadministration of trastuzumab and anthracyclines].
    Wilhelm M
    Strahlenther Onkol; 2014 Apr; 190(4):428-9. PubMed ID: 24638245
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of HER2-positive breast cancer: looking backwards briefly.
    Puhalla S; Brufsky A
    Lancet Oncol; 2013 Dec; 14(13):1250-1. PubMed ID: 24239207
    [No Abstract]   [Full Text] [Related]  

  • 3. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.
    Buzdar AU; Suman VJ; Meric-Bernstam F; Leitch AM; Ellis MJ; Boughey JC; Unzeitig G; Royce M; McCall LM; Ewer MS; Hunt KK;
    Lancet Oncol; 2013 Dec; 14(13):1317-25. PubMed ID: 24239210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?
    Esteva FJ; Hortobagyi GN
    J Natl Cancer Inst; 2008 Apr; 100(8):521-3. PubMed ID: 18398093
    [No Abstract]   [Full Text] [Related]  

  • 5. [HER2-positive breast cancer: standard and double targeted therapy].
    Semiglazov VF; Bozhok AA; Semiglazova TIu; Vasil'ev AG; Manikhas AG; Semiglazov VV; Bessonov AA; Nikolaev KS
    Vopr Onkol; 2013; 59(3):341-6. PubMed ID: 23909035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy.
    Prat A; Baselga J
    J Clin Oncol; 2013 May; 31(14):1703-6. PubMed ID: 23569319
    [No Abstract]   [Full Text] [Related]  

  • 7. [BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
    Semiglazov VF; Semiglazov VV; Petrenko OL; Komyakhov AV; Dashyan GA; Paltuev RM; Semiglazova TY; Manikhas AG; Bozhok AA; Lalak IA
    Vopr Onkol; 2015; 61(3):381-6. PubMed ID: 26242149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.
    Musolino A; Naldi N; Dieci MV; Zanoni D; Rimanti A; Boggiani D; Sgargi P; Generali DG; Piacentini F; Ambroggi M; Cagossi K; Gianni L; Sarti S; Bisagni G; Ardizzoni A; Conte PF; Guarneri V
    Pharmacogenomics J; 2016 Oct; 16(5):472-7. PubMed ID: 27378608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?
    Del Mastro L; Bighin C; Bini G; Giraudi S; Taveggia P; Levaggi A; Canavese G; Rescinito G; Pronzato P
    Ann Oncol; 2010 Jun; 21(6):1376-1377. PubMed ID: 20430904
    [No Abstract]   [Full Text] [Related]  

  • 11. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
    van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
    Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
    Brower V
    J Natl Cancer Inst; 2013 Jun; 105(12):835-6. PubMed ID: 23733910
    [No Abstract]   [Full Text] [Related]  

  • 13. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
    Rowan K
    J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
    [No Abstract]   [Full Text] [Related]  

  • 14. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
    Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant trials could speed up drug approvals.
    Peres J
    J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
    [No Abstract]   [Full Text] [Related]  

  • 16. [Gastrointestinal injuries in patients with breast cancer treated with chemotherapy].
    Koroleva IA; Vel'sher LZ; Kaziulin AN; Kucheriavyĭ IuA; Oganesian TS
    Vopr Onkol; 2010; 56(2):206-9. PubMed ID: 20552899
    [No Abstract]   [Full Text] [Related]  

  • 17. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
    Baselga J; Bradbury I; Eidtmann H; Di Cosimo S; de Azambuja E; Aura C; Gómez H; Dinh P; Fauria K; Van Dooren V; Aktan G; Goldhirsch A; Chang TW; Horváth Z; Coccia-Portugal M; Domont J; Tseng LM; Kunz G; Sohn JH; Semiglazov V; Lerzo G; Palacova M; Probachai V; Pusztai L; Untch M; Gelber RD; Piccart-Gebhart M;
    Lancet; 2012 Feb; 379(9816):633-40. PubMed ID: 22257673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.
    Stoen E; Kabos P; Borden KC; Brown RJ; Borges VF; Diamond JR
    Oncology (Williston Park); 2018 Jun; 32(6):298-302. PubMed ID: 29940061
    [No Abstract]   [Full Text] [Related]  

  • 19. Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?
    Tarantino P; Tolaney SM; Harbeck N; Cortes J; Curigliano G
    J Clin Oncol; 2021 Nov; 39(32):3541-3545. PubMed ID: 34406849
    [No Abstract]   [Full Text] [Related]  

  • 20. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
    Esteva FJ; Wang J; Lin F; Mejia JA; Yan K; Altundag K; Valero V; Buzdar AU; Hortobagyi GN; Symmans WF; Pusztai L
    Breast Cancer Res; 2007; 9(6):R87. PubMed ID: 18086299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.